Drug intelligence / Profile preview

fulvestrant + lerociclib

Development stage: Unknown
Lead developer: Genor Biopharma
Modality: Small Molecules
Administration: Oral, Intramuscular

Overview

Combination of fulvestrant and lerociclib for the treatment of hormone receptor-positive (HR+), HER2-negative advanced breast cancer. Lerociclib is a highly selective oral CDK4/6 inhibitor that has demonstrated anti-tumor activity with a differentiated safety and tolerability profile. This combination has shown significant improvement in progression-free survival compared to fulvestrant alone in patients whose disease had progressed on prior endocrine therapy.

Other names: GB491 + fulvestrantlerociclib and fulvestrant

Targets

CDK4 (Cyclin-dependent kinase 4)ESR1 (ERα)CDK9 (Cyclin-dependent kinase 9)ESR2 (ERβ)CDK6 (Cyclin-dependent kinase 6)

Beyond the preview

Go deeper on fulvestrant + lerociclib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fulvestrant + lerociclib.

Explore the full profile